European Journal of Heart Failure

DECEMBER 20, 2023

Abstract Cardio-oncology is a rapidly growing field of cardiovascular (CV) medicine that has resulted from the continuously increasing clinical demand for specialized CV evaluation, prevention and management of patients suffering or surviving from malignant diseases.

Cardio Oncology 75

Cardio Oncology Cancer Certification Document 75

Becker's Hospital Review - Cardiology

DECEMBER 14, 2023

NYU Langone Health in New York City has appointed Michelle Bloom, MD, as system director of its cardio-oncology program, effective Dec.

Cardio Oncology 62

Cardio Oncology 62

HCPLive

FEBRUARY 13, 2024

and sleep apnea prevalence in cardio-oncology patients was the same or greater than other traditional risk factors. Sleep apnea prevalence in cardiology patients was similar to the rates in patients with heart failure.,

Cardio Oncology 59

Cardio Oncology Risk Factors Heart Failure 59

Frontiers in Cardiovascular Medicine

FEBRUARY 28, 2024

Cangrelor, a potent intravenous P2Y12 platelet inhibitor, has demonstrated effectiveness in reducing ischemic events without a corresponding increase in severe bleeding during percutaneous coronary intervention, as evidenced by the CHAMPION-PHOENIX trial.

Cardio Oncology 69

Cardio Oncology Cancer Patient Care Research 69

DAIC

FEBRUARY 28, 2024

The emerging field of cardio-oncology is paving the way for expert, multidisciplinary heart care before, during and after cancer treatment to mitigate adverse effects on cardiovascular health.

Risk Factors 88

Risk Factors Cancer Cardio Oncology Blood Pressure 88

DAIC

FEBRUARY 2, 2024

After two full days covering a wide range of issues and experts, the final day will include a joint session with the American College of Cardiology ( ACC ) and the American Society of Clinical Oncology ( ASCO ). Cardio-Oncology Educational Training: What Do I Need to Learn? How to Structure?:

Cardio Oncology 64

Cardio Oncology Cancer Pharmacology RN 64

Frontiers in Cardiovascular Medicine

JANUARY 19, 2024

The baseline risk of CTRCD was graded according to the risk score proposed by the Heart Failure Association (HFA) Cardio-Oncology Working Group and the International Cardio-Oncology Society (ICOS). CTRCD and its severity were defined according to the current European Society of Cardiology (ESC) guidelines.

Cardio Oncology 64

Cardio Oncology Cancer Heart Failure Risk Factors 64